Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting.

Biologics imaging immunogenicity mAb non-clinical safety pharmacokinetics

Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
Historique:
entrez: 9 7 2021
pubmed: 10 7 2021
medline: 29 12 2021
Statut: ppublish

Résumé

New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019. The session topics were selected by European BioSafe organization committee members based on recent company achievements, agency interactions and new data obtained in the non-clinical safety testing of biotherapeutics, for which data sharing would be of interest and considered as valuable information. The presented session topics ranged from strategies of

Identifiants

pubmed: 34241561
doi: 10.1080/19420862.2021.1938796
pmc: PMC8274438
doi:

Types de publication

Congress

Langues

eng

Sous-ensembles de citation

IM

Pagination

1938796

Références

Vaccine. 2011 Apr 12;29(17):3299-309
pubmed: 21349362
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
MAbs. 2012 Jul-Aug;4(4):475-87
pubmed: 22699308
Regul Toxicol Pharmacol. 2016 Nov;81:448-456
pubmed: 27743776
Eur J Immunol. 2016 May;46(5):1291-9
pubmed: 26865269
Regul Toxicol Pharmacol. 2015 Oct;73(1):265-75
pubmed: 26219199
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
pubmed: 1690918
Front Immunol. 2019 Mar 28;10:601
pubmed: 31001248
Regul Toxicol Pharmacol. 2014 Jul;69(2):226-33
pubmed: 24755365
Drug Metab Dispos. 2019 Dec;47(12):1443-1456
pubmed: 31748266
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Birth Defects Res B Dev Reprod Toxicol. 2009 Apr;86(2):98-107
pubmed: 19294679
Drug Metab Dispos. 2014 Nov;42(11):1858-66
pubmed: 25185260
Bioanalysis. 2016 Mar;8(6):483-6
pubmed: 26915368
Comput Toxicol. 2019 Feb;9:61-72
pubmed: 31008414
Methods Mol Biol. 2017;1612:1-11
pubmed: 28634931
Regul Toxicol Pharmacol. 2016 Oct;80S:S1-S14
pubmed: 27578450
Eur J Pharm Biopharm. 2016 Mar;100:94-100
pubmed: 26775146
Bioanalysis. 2014 Mar;6(6):859-79
pubmed: 24702115
J Pharm Sci. 2019 Apr;108(4):1366-1377
pubmed: 30471292
MAbs. 2020 Jan-Dec;12(1):1707418
pubmed: 31924123
Front Big Data. 2019 Jul 17;2:25
pubmed: 33693348
EJNMMI Res. 2019 May 21;9(1):45
pubmed: 31115711
Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1640-1641
pubmed: 31642154
Bioanalysis. 2014;6(23):3225-35
pubmed: 25529889
Drug Discov Today. 2013 Dec;18(23-24):1138-43
pubmed: 23942260
Bioanalysis. 2018 Aug 1;10(16):1261-1272
pubmed: 29923414
PLoS One. 2014 Jun 24;9(6):e100736
pubmed: 24959685
Altern Lab Anim. 2009 Sep;37 Suppl 1:19-27
pubmed: 19807200
Front Immunol. 2017 May 05;8:500
pubmed: 28529511
Oncoimmunology. 2019 Nov 24;9(1):1682381
pubmed: 32002290
AAPS J. 2011 Mar;13(1):99-110
pubmed: 21240643
Birth Defects Res B Dev Reprod Toxicol. 2009 Apr;86(2):108-16
pubmed: 19283862
Anal Chem. 2016 Feb 2;88(3):1871-7
pubmed: 26713683
Pharm Res. 2015 Jul;32(7):2344-59
pubmed: 25630815
Birth Defects Res B Dev Reprod Toxicol. 2009 Aug;86(4):328-44
pubmed: 19626656
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077-81
pubmed: 2762315
Expert Rev Clin Pharmacol. 2019 Jun;12(6):537-545
pubmed: 30977686
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Artif Organs. 2006 Oct;30(10):803-8
pubmed: 17026580
Biostatistics. 2019 Apr 1;20(2):273-286
pubmed: 29394327
MAbs. 2014 Mar-Apr;6(2):327-39
pubmed: 24441081
Regul Toxicol Pharmacol. 2018 Apr;94:91-100
pubmed: 29355662
Regul Toxicol Pharmacol. 2018 Oct;98:69-79
pubmed: 30009863

Auteurs

Thomas Kissner (T)

Preclinical Safety, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.

Guenter Blaich (G)

Preclinical Safety, AbbVie Deutschland GmbH, Ludwigshafen, Germany.

Andreas Baumann (A)

R&D Pharmaceuticals, Translational Sciences, Bayer AG, Berlin, Germany.

Sven Kronenberg (S)

Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Adam Hey (A)

Oncology Safety, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.

Andrea Kiessling (A)

Preclinical Safety, Novartis Pharma, Basel, Switzerland.

Petra M Schmitt (PM)

Preclinical Safety, AbbVie Deutschland GmbH, Ludwigshafen, Germany.

Wouter Driessen (W)

Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Chantal Carrez (C)

Sanofi R&D, Translational In Vivo Models, Sanofi S.A, Vitry-sur-Seine, France.

Daniel Kramer (D)

Sanofi R&D, Translational Medicine & Early Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.

Jennifer Fretland (J)

Drug Metabolism and Pharmacokinetics, Sanofi US, Waltham, MA, USA.

Wolfgang F Richter (WF)

Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Tobias Paehler (T)

Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.

Ulrike Hopfer (U)

Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Benno Rattel (B)

Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH